Information Provided By:
Fly News Breaks for July 30, 2019
QURE
Jul 30, 2019 | 07:20 EDT
Guggenheim analyst Whitney Ijem downgraded uniQure to Neutral from Buy without a price target. The analyst continues to see value in the company's lead program AMT-061 for hemophilia B, earlier stage pipeline, and wholly owned manufacturing capability. However, with the shares up 127% year-to-date and a "relatively catalyst light" second half of 2019, Ijem prefers to step the sidelines.
News For QURE From the Last 2 Days
There are no results for your query QURE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.